Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery
Albialy, H., Wagih, M., Gouda, D., Eid, A. (2022). Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery. EKB Journal Management System, 28(6.2), 74-80. doi: 10.21608/zumj.2019.19166.1616
Hany Abdalhafiz Albialy; Mostafa Mohammed Wagih; Doaa Mohammed Gouda; ashraf mahrous Eid. "Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery". EKB Journal Management System, 28, 6.2, 2022, 74-80. doi: 10.21608/zumj.2019.19166.1616
Albialy, H., Wagih, M., Gouda, D., Eid, A. (2022). 'Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery', EKB Journal Management System, 28(6.2), pp. 74-80. doi: 10.21608/zumj.2019.19166.1616
Albialy, H., Wagih, M., Gouda, D., Eid, A. Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery. EKB Journal Management System, 2022; 28(6.2): 74-80. doi: 10.21608/zumj.2019.19166.1616

Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery

Zagazig University Medical Journal
Article 12, Volume 28, Issue 6.2, November 2022, Page 74-80  XML PDF (299.06 K)
Document Type: Original Article
DOI: 10.21608/zumj.2019.19166.1616
View on SCiNiTO View on SCiNiTO
Authors
Hany Abdalhafiz Albialy email orcid 1; Mostafa Mohammed Wagihorcid 2; Doaa Mohammed Goudaorcid 3; ashraf mahrous Eidorcid 4
1Departmemt of ophthalmology,faculity of medicine , Zagazig university0000
2Ophthalmology Department, Zagazig University, Zagazig, Egypt
3Zagazig ophthalmic hospital, Zagazig, Egypt
4ophthalmology department, faculty of medicine, zagazig university
Abstract
Background:
To evaluate whether intracameral dexamethasone – moxifloxacin can safely and effectively reduce the postoperative inflammation, guard against endophthalmitis and improve surgical outcomes after cataract surgery.
Methods:
Prospective randomized comparative study included 200 eyes of 200 Patients underwent uncomplicated phacoemulsification . 100 eyes were injected intracamerally with 0.1 ml moxifloxacin 0.5% and 0.4 mg dexamethasone at the end of surgery while the other 100 eyes as a control group received intracameral placebo injection. Outcomes were measured on first postoperative day and weekly for one month by visual acuity assessment, slit lamp examination, intraocular pressure , endothelial cell density and any postoperative complications.
Results:
Aqueous cells on the first postoprative day in group I : five eyes had 2+, and 7 eyes had 1+ with no eyes of +3 or more. After 1 week , all eyes had no anterior chamber cells. In group II, the first postoperative day showed 11 eyes with 3+, 15 eyes had 2+, 8 eyes had 1+. One week postoperatively , only 3 eyes had +1 aquous cells. All eyes of both groups had no detected anterior chamber cells at subsequent follow up visits. The mean postoperative endothelial cell density in injectedgroup was 2274.15 cells/mm2 ±330.09. after one month . There was no significant effect on IOP values with no detected long-term complications .
Conclusion:
Intracameral dexamethasone- moxifloxacin injected at the end of cataract surgery reduces the postoperative AC cells significantly and improves patient's compliance in early postoperative follow period with no risk of IOP elevation.
Keywords
Keywords: cataract surgery; intracameral; dexamethasone; moxifoxacin
Statistics
Article View: 650
PDF Download: 269